World's Best Scientists 2026 revealed!

D-Index & Metrics

Chemistry

D-Index
43
Citations
8897
World Ranking
17086
National Ranking
1236

John T. Hunt publication distribution in Chemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Chemistry in 2026. The highlighted bar marks where John T. Hunt sits on this spectrum.

61–80 publications: 66 scientists 81–100 publications: 302 scientists 101–120 publications: 623 scientists 121–140 publications: 918 scientists 141–160 publications: 1,218 scientists 161–180 publications: 1,350 scientists 181–200 publications: 1,344 scientists 201–220 publications: 1,281 scientists 221–240 publications: 1,216 scientists 241–260 publications: 1,100 scientists 261–280 publications: 979 scientists 281–300 publications: 939 scientists 301–320 publications: 764 scientists 321–340 publications: 643 scientists 341–360 publications: 628 scientists 361–380 publications: 522 scientists 381–400 publications: 459 scientists 401–420 publications: 397 scientists 421–440 publications: 327 scientists 441–460 publications: 270 scientists 461–480 publications: 265 scientists 481–500 publications: 252 scientists 501–520 publications: 201 scientists 521–540 publications: 185 scientists 541–560 publications: 148 scientists 561–580 publications: 148 scientists 581–600 publications: 132 scientists 601–620 publications: 114 scientists 621–640 publications: 104 scientists 641–660 publications: 91 scientists 661–680 publications: 92 scientists 681–700 publications: 73 scientists 701–720 publications: 57 scientists 721–740 publications: 54 scientists 741–760 publications: 67 scientists 761–780 publications: 45 scientists 781–800 publications: 46 scientists 801–820 publications: 39 scientists 821–840 publications: 32 scientists 841–860 publications: 36 scientists 861–880 publications: 29 scientists 881–900 publications: 26 scientists 901–920 publications: 24 scientists 921–940 publications: 14 scientists 941–960 publications: 23 scientists 961–980 publications: 28 scientists 981–1,000 publications: 15 scientists 1,001–1,020 publications: 29 scientists 1,021–1,040 publications: 12 scientists 1,041–1,060 publications: 19 scientists 1,061–1,080 publications: 12 scientists 1,081–1,100 publications: 6 scientists 1,101–1,120 publications: 8 scientists 1,121–1,140 publications: 12 scientists 1,141–1,160 publications: 5 scientists 1,161–1,180 publications: 6 scientists 1,181–1,200 publications: 14 scientists 1,201–1,220 publications: 7 scientists 1,221–1,240 publications: 2 scientists 1,241–1,260 publications: 6 scientists 1,261–1,280 publications: 4 scientists 1,281–1,294 publications: 6 scientists 1,295+ publications: 100 scientists
61 publications 1,295+

This scientist: 115 publications — 4th percentile

4% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,295 publications or more.

John T. Hunt D-index placement in Chemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Chemistry scientists ranked by Research.com in 2026. The highlighted bar marks where John T. Hunt sits on this spectrum.

40–41 D-Index: 289 scientists 42–43 D-Index: 612 scientists 44–45 D-Index: 808 scientists 46–47 D-Index: 776 scientists 48–49 D-Index: 835 scientists 50–51 D-Index: 861 scientists 52–53 D-Index: 872 scientists 54–55 D-Index: 933 scientists 56–57 D-Index: 1,051 scientists 58–59 D-Index: 930 scientists 60–61 D-Index: 882 scientists 62–63 D-Index: 834 scientists 64–65 D-Index: 731 scientists 66–67 D-Index: 775 scientists 68–69 D-Index: 683 scientists 70–71 D-Index: 646 scientists 72–73 D-Index: 561 scientists 74–75 D-Index: 501 scientists 76–77 D-Index: 437 scientists 78–79 D-Index: 388 scientists 80–81 D-Index: 354 scientists 82–83 D-Index: 292 scientists 84–85 D-Index: 275 scientists 86–87 D-Index: 254 scientists 88–89 D-Index: 235 scientists 90–91 D-Index: 185 scientists 92–93 D-Index: 192 scientists 94–95 D-Index: 155 scientists 96–97 D-Index: 163 scientists 98–99 D-Index: 125 scientists 100–101 D-Index: 105 scientists 102–103 D-Index: 105 scientists 104–105 D-Index: 112 scientists 106–107 D-Index: 88 scientists 108–109 D-Index: 68 scientists 110–111 D-Index: 69 scientists 112–113 D-Index: 65 scientists 114–115 D-Index: 79 scientists 116–117 D-Index: 61 scientists 118–119 D-Index: 44 scientists 120–121 D-Index: 37 scientists 122–123 D-Index: 40 scientists 124–125 D-Index: 33 scientists 126–127 D-Index: 26 scientists 128–129 D-Index: 34 scientists 130–131 D-Index: 35 scientists 132–133 D-Index: 25 scientists 134–135 D-Index: 27 scientists 136–137 D-Index: 17 scientists 138–139 D-Index: 16 scientists 140–141 D-Index: 20 scientists 142–143 D-Index: 20 scientists 144–145 D-Index: 15 scientists 146–147 D-Index: 9 scientists 148–149 D-Index: 9 scientists 150–151 D-Index: 16 scientists 152–153 D-Index: 11 scientists 154–155 D-Index: 9 scientists 156–157 D-Index: 3 scientists 158 D-Index: 3 scientists 159+ D-Index: 98 scientists
40 D-Index 159+

This scientist: 43 D-Index — 5th percentile

5% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 159 D-Index or more.

Overview

John T. Hunt is affiliated with Bristol-Myers Squibb in Germany. Their research activity spans several fields, primarily within Medicine, Neuroscience, and Biochemistry, Genetics and Molecular Biology. The scientist has contributed notably to subfields such as Biological Psychiatry, Molecular Biology, Pharmacology, Oncology, and Behavioral Neuroscience.

Their work addresses topics that include Tryptophan and brain disorders, Stress Responses and Cortisol, Treatment of Major Depression, Bipolar Disorder and Treatment, Pharmacological Receptor Mechanisms and Effects, Pharmacogenetics and Drug Metabolism, as well as Immunotherapy and Immune Responses.

Frequent publication venues for their research include:

  • ACS Medicinal Chemistry Letters
  • Journal for ImmunoTherapy of Cancer
  • Molecular Cancer Therapeutics
  • Journal of Medicinal Chemistry
  • Bioorganic & Medicinal Chemistry Letters

Recent publications reflect an emphasis on cancer immunotherapy and pharmacological inhibitor development. Selected papers include:

  • Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor, 2021, Journal for ImmunoTherapy of Cancer
  • Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor, 2020, Molecular Cancer Therapeutics
  • Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug Design, 2021, Journal of Medicinal Chemistry
  • Discovery and Preclinical Evaluation of BMS-986242, a Potent, Selective Inhibitor of Indoleamine-2,3-dioxygenase 1, 2021, ACS Medicinal Chemistry Letters
  • Discovery of Imidazopyridines as Potent Inhibitors of Indoleamine 2,3-Dioxygenase 1 for Cancer Immunotherapy, 2021, ACS Medicinal Chemistry Letters

The scientist collaborates frequently with other researchers, including Aaron Balog, Sarah C. Traeger, Johnni Gullo-Brown, Tai-an Lin, and Derrick Maley.

Best Publications

  • Inhibitors of farnesyl protein transferase

    Rajeev S. Bhide;Charles Z. Ding;John T. Hunt;Soong-Hoon Kim

  • Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

    Louis J. Lombardo;Francis Y. Lee;Ping Chen;Derek Norris

  • Discovery of N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily

    Gretchen M. Schroeder;Yongmi An;Zhen-Wei Cai;Xiao-Tao Chen

  • N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent.

    Raj N Misra;Hai-yun Xiao;Kyoung S Kim;Songfeng Lu

  • Venous smooth muscle contains vasoconstrictor ETB-like receptors

    Suzanne Moreland;Diane M. McMullen;Carol L. Delaney;Ving G. Lee

  • Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form.

    Micah T. Nelp;Patrick A. Kates;John T. Hunt;John A. Newitt

  • The discovery of sulfonamide endothelin antagonists and the development of the orally active ETA antagonist 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulf onamide.

    Stein Pd;Hunt Jt;Floyd Dm;Moreland S

  • Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-Ray Crystallographic Analysis, and Biological Activities

    Kyoung Soon Kim;S. David Kimball;Raj N. Misra;David B. Rawlins

  • Pyrrolotriazine inhibitors of kinases

    John T. Hunt;Rajeev S. Bhide;Robert Michael Borzilleri;Ligang Qian

  • Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor.

    Rajeev S. Bhide;Zhen-Wei Cai;Yong-Zheng Zhang;Ligang Qian

  • Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).

    Zhen-wei Cai;Yongzheng Zhang;Robert M. Borzilleri;Ligang Qian

  • Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity.

    John T. Hunt;Charles Z. Ding;Roberta Batorsky;Mark Bednarz

  • Aminothiazole inhibitors of cyclin dependent kinases

    Kyoung S. Kim;S. David Kimball;Zhen-wei Cai;David B. Rawlins

  • Discovery of the Pyrrolo[2,1-f][1,2,4]triazine Nucleus as a New Kinase Inhibitor Template

    John T Hunt;Toomas Mitt;Robert Borzilleri;Johnni Gullo-Brown

  • Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological activities.

    Kyoung Soon Kim;Liping Zhang;Robert Schmidt;Zhen-Wei Cai

  • Discovery of ixabepilone.

    John T. Hunt

  • Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects.

    K S Kim;J S Sack;J S Tokarski;L Qian

  • Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models.

    Maria Jure-Kunkel;Gregg Masters;Emel Girit;Gennaro Dito

  • Sulfonamide endothelin antagonists

    Philip D. Stein;John T. Hunt;Natesan Murugesan

  • Potent, Cell Active, Non-Thiol Tetrapeptide Inhibitors of Farnesyltransferase

    John T. Hunt;Ving G. Lee;Katerina Leftheris;Bernd Seizinger

  • Discovery of Clinical Candidate BMS-906024: A Potent Pan-Notch Inhibitor for the Treatment of Leukemia and Solid Tumors.

    Ashvinikumar V. Gavai;Claude Quesnelle;Derek Norris;Wen-Ching Han

Frequent Co-Authors

Joel C. Barrish
Joel C. Barrish Bristol-Myers Squibb (Germany)
George L. Trainor
George L. Trainor Bristol-Myers Squibb (Germany)
Yufen Zhao
Yufen Zhao Xiamen University
Marco M. Gottardis
Marco M. Gottardis NKGen Biotech Inc
Andrew V. Kossenkov
Andrew V. Kossenkov The Wistar Institute
Bernd R. Seizinger
Bernd R. Seizinger Oxford Biotherapeutics (United Kingdom)
Dmitry I. Gabrilovich
Dmitry I. Gabrilovich AstraZeneca (United Kingdom)
Scott I. Abrams
Scott I. Abrams Roswell Park Cancer Institute
Niels H. Andersen
Niels H. Andersen University of Washington

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students pursuing Chemistry in the USA, a variety of related career pathways offer promising opportunities. Those interested in law and science may explore a paralegal certificate, which combines legal knowledge with scientific understanding, opening doors to specialized legal roles in chemical patents and intellectual property.

Another popular option is entering the pharmaceutical industry. Becoming a pharmaceutical sales representative is a rewarding career with competitive earning potential. Learning more about pharmaceutical rep salary can help students weigh this path’s benefits and expectations.

For those wondering about the challenges of healthcare careers, understanding is it hard to become a pharmacist sheds light on the rigorous education and dedication required. Chemistry graduates often find this field rewarding, as pharmacists play a crucial role in medication management and patient care.

Lastly, a niche yet fascinating path is becoming an autopsy technician. This role requires specialized education, and students can benefit from guidance on how to become an autopsy technician, which explores necessary training and job outlook in forensic science.

Best Scientists Citing John T. Hunt

Trending Scientists

Recently Published Articles